INTRODUCTION
Follicular lymphoma (FL) is the second most common subtype of adult B-cell non-Hodgkin lymphoma (NHL) in Western countries. Most FL patients have incurable disease with a generally indolent course with frequent relapses. The eventual development of resistance to chemotherapy or transformation to diffuse large B-cell lymphoma (tFL to DLBCL) will lead to death from disease. Despite a common underlying genetic abnormality, the clinical course of FL patients is High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation Joaquim Carreras, 1) Armando Lopez-Guillermo, 2) Yara Yukie Kikuti, 1) Johbu Itoh, 1) Miyaoka Masashi, 1) Haruka Ikoma, 1) Sakura Tomita, 1) Shinichiro Hiraiwa, 1) Rifat Hamoudi, 3) Andreas Rosenwald, 4) Ellen Leich, 4) Antonio Martinez, 5) Giovanna Roncador, 6) Neus Villamor, 2) Lluis Colomo, 7) Patricia Perez, 2) Noriko M Tsuji, 8) Elias Campo 5) and Naoya Nakamura 1) The microenvironment influences the behavior of follicular lymphoma (FL) but the specific roles of the immunomodulatory BTLA and TNFRSF14 (HVEM) are unknown. Therefore, we examined their immunohistochemical expression in the intrafollicular, interfollicular and total histological compartments in 106 FL cases (57M/49F; median age 57-years), and in nine relapsed-FL with transformation to DLBCL (tFL). BTLA expression pattern was of follicular T-helper cells (TFH) in the intrafollicular and of T-cells in the interfollicular compartments. The mantle zones were BTLA+ in 35.6% of the cases with similar distribution of IgD. TNFRSF14 expression pattern was of neoplastic B lymphocytes (centroblasts) and "tingible body macrophages". At diagnosis, the averages of total BTLA and TNFRSF14-positive cells were 19.2%±12.4STD (range, 0.6%-58.2%) and 46.7 cells/HPF (1-286.5), respectively. No differences were seen between low-grade vs. high-grade FL but tFL was characterized by low BTLA and high TNFRSF14 expression. High BTLA correlated with good overall survival (OS) (total-BTLA, Hazard Risk=0.479, P=0.022) and with high PD-1 and FOXP3+Tregs. High TNFRSF14 correlated with poor OS and progression-free survival (PFS) (total-TNFRSF14, HR=3.9 and 3.2, respectively, P<0.0001), with unfavorable clinical variables and higher risk of transformation (OR=5.3). Multivariate analysis including BTLA, TNFRSF14 and FLIPI showed that TNFRSF14 and FLIPI maintained prognostic value for OS and TNFRSF14 for PFS. In the GSE16131 FL series, high TNFRSF14 gene expression correlated with worse prognosis and GSEA showed that NFkB pathway was associated with the "High-TNFRSF14/dead-phenotype".
In conclusion, the BTLA-TNFRSF14 immune modulation pathway seems to play a role in the pathobiology and prognosis of FL.
Keywords: Follicular lymphoma, transformed follicular lymphoma, TNFRSF14 (HVEM), BTLA, immune microenvironment heterogeneous. Therefore, it is important to identify the high-risk patients who will experience rapid disease progression. [1] [2] [3] [4] In hematological malignancies the tumor microenvironment plays a critical role in tumorigenesis. 5 In the case of FL, the intimate relationship between the tumor microenvironment and the neoplastic cells implies a dynamic cross-talk in which tumor cells may give and receive instructions through a complex system. 5 Several lines of investigations have highlighted that FL is an immunologically functional disease in which an active interaction between tumor cells and the functional composition of the microenvironment determines the prognosis and response to treatment. 6 Gene expression profiling studies revealed that survival after initial diagnosis of FL could be predicted by biological differences. The "immune-response type 1 signature" included genes encoding T-cell markers and macrophages and was associated with a good prognosis. In contrast, the "immuneresponse type 2 signature" that included genes expressed in macrophages and dendritic cells associated with a poor prognosis. 7 Immunohistochemical studies were developed to better characterize the FL microenvironment and its influence on the disease outcome. Early studies strongly suggested that a high frequency of CD68+tumor-associated macrophages (TAMs) in FL were associated with a poor prognosis and later confirmed that this poor prognosis was due to M2-like CD163+TAMs. 8, 9 Regulatory FOXP3+T lymphyocytes (Tregs) account for 5-10% of CD4+T-cells and have immune suppressive functions. 10 Several studies have shown that a high frequency of Tregs in FL is associated with a good prognosis and a reduced risk of transformation. 1, 11 In addition, the architectural pattern of Tregs' infiltration in FL nodes also had an effect: a diffuse pattern was associated with a good prognosis but a follicular or perifollicular pattern was associated with poor prognosis. 11 Programmed cell death protein 1 (PD-1, also known as PDCD1 and CD279) is a member of the CD28 superfamily of membrane receptors that have an important function in the regulation of immune responses and in the tolerance to self-antigens as well as to tumor cells. 12 In our previous study, a high frequency of PD-1-positive cells infiltrating the tumor correlated with favorable survival in patients with FL, independently of the FLIPI; and similar results were obtained by another group. 3, 13 Overall, these results suggest that the prognosis of FL depends on several immune cell subsets and pathways working simultaneously rather than being dictated by an individual immune cell subset. 6 A marker related to PD-1 is B-and T-lymphocyte attenuator (BTLA) and they are both expressed by T follicular helper cells (TFH cells).
14 BTLA ligand is the Tumor necrosis factor receptor superfamily member 14 (TNFRSF14, also known as HVEM). 15 BTLA and TNFRSF14 crosstalk regulates inhibition and costimulation of several key players of the immune system: BTLA functions as an inhibitory receptor in T lymphocytes 16 while the ligand TNFRSF14 produces proinflammatory signals via activation of NF-kappaB 17 and it is expressed by antigen presenting cells. 18 Interestingly, TNFRSF14 aberrations in FL increase clinically significant allogeneic T-cell responses 19 and in nonsmall cell lung cancer TNFRSF14 may contribute to the immune escape. 20 In this study, we have examined a series of FL patients at diagnosis and after transformation to DLBCL to determine the role of the BTLA and TNFRSF14 immune checkpoint in the progression and outcome of FL.
MATERIALS AND METHODS

Patients and samples
106 diagnostic biopsies of Western FL patients diagnosed in a single institution between 1978 and 2008 were included in the study, reviewed and re-classified according to the WHO classification. 21 The median age of the patients was 57 years (range, 
Immunohistochemical procedures and quantitative assessment
Whole tissue sections from paraffin embedded samples were immunostained using undiluted hybridoma supernatant of anti-BTLA murine monoclonal antibody (AM-005, clone FLO67B, Monoclonal Antibodies Unit, Spanish National Cancer Research Centre, CNIO, Madrid, Spain), anti-TNFRSF14 (Rabbit polyclonal to TNFRSF14 -Aminoterminal end, ab47677, Abcam, Cambridge, UK) and anti-IgD (FLEX Anti-IgD, Code IR517/IS517, Dako Diagnosticos, S.A., Barcelona, Spain). Immunohistochemical staining was automatically performed using a Leica BOND-MAX immunostainer according to manufacturer's instructions (Leica Microsystems, L'Hospitalet de Llobregat, Spain). Eightythree and 91 cases previously studied for FOXP3 and PD-1 (NAT105) were included in this series. Follicular and interfol·licular BTLA-positive cells were quantified using an automated scanning microscope and computerized digital image analysis system always under pathologist visual supervision as previously described (Ariol SL-50, Leica Biosystems, Barcelona, Spain). 1, 3 Briefly, quantification was performed using the gensight multistain assay. Whole tissue sections were automatically scanned at 10x followed by directed high magnification at 200x. Color and shape definition parameters were first assessed and then recalibrated among tissue samples. Positive and negative pixels were counted independently in the follicular and interfol·licular compartments. The follicular compartment included the mantle zone when present. Once the areas of interest were selected the software collected the data automatically. The presence or absence of a BTLA-positive mantle zone (which means that all cells in the mantle were positive) was annotated as a qualitative variable. The number of TNFRSF14-positive cells was quantified as number of positive cells per HPF (400x magnification; Olympus BX51, UPlanFI 40x/0.75; Olympus UK Ltd, Essex, UK). The percentage of BTLA and number of TNFRSF14 positive cells was recorded in the follicular and interfollicular compartments and then the total value was calculated.
Immunofluorescence was performed using biotinylated goat anti-mouse and anti-rabbit IgG antibodies (#BA-9200 and BA-1000, Vector Laboratories, CA, USA), streptavidin, Alexa Fluor 488 and 568 conjugates and ProLong™ Gold antifade mountant with DAPI (#S11223, S11226 and #P36941, Thermo Fisher Scientific K.K., Tokyo, Japan). Zeiss LSM700 laser-scanning confocal microscope was used with linear unmixing and spectral imaging following the manufacurer's instructions (Zeiss, Tokyo, Japan) with combination to Imaris microscopy image analysis software (Bitplane AG, Zurich, Switzerland). Human reactive lymphoid tissue was used to analyze the expression of TNFRSF14 and BTLA with FOXP3 and PD-1 using the double or triple immunofluorescence stainings. In addition, relationship of TNFRSF14 with PAX5 (B-cells), CD21 (FDCs) and MITF (macrophages) was analyzed as well using Bond Polymer Refine Red Detection (#DS9390) and Bond Polymer Refine DAB Detection (#DS9800).
Lymphoid tissue from peyer's patches of small intestine of control BALB/c mice were studied by flow cytometry to quantify the expression frequency of BTLA and TNFRSF14 against the markers of B220 (CD45R), CD11C and FOXP3 as described. 22 Same antibodies were used for direct immunofluorescence in frozen tissue.
Gene expression analysis
The online SurvExpress tool 23 was used to correlate the gene expression levels with the patients' outcome of the previously published series of Dave et al. that includes 191 FL cases. 7 Then, the same FL gene expression and clinical features datasets were downloaded from the NCBI, Gene Expression Omnibus (GEO), series GSE16131, platform GPL96 [HG-U133A], Affymetrix human genome U133A array), series matrix file. Gene Set Enrichment Analysis (GSEA) was performed following the Broad Institute software and their instructions. 24, 25 To narrow the differences we compared the GSEA between 30 cases of high TNFRSF14 and dead phenotype vs. 30 cases of low TNFRSF14 and alive phenotype. The target pathway to test was the NFkB immune inflammatory gene set, M2645, "hinata", homo sapiens, from the Molecular Signatures Database of Broad Institute.
Statistical analysis
The main initial and evolutive variables were analyzed for prognostic significance. BTLA and TNFRSF14-positivecells were initially quantified and analyzed as a continuous variable and later the best threshold for overall survival was found using Cutoff Finder software. 26 Comparison of means was performed with independent-samples T Test, and nonparametric tests (independent samples) to automatically compare distributions across groups when required. Categorical data were compared using crosstabs, chi-square, using 
RESULTS
Clinical and histological features of the patients at diagnosis
The main clinical and histological features of the 106 patients at diagnosis are detailed in the methods section and summarized in Table 1 and Tables 2.1 and 2. 2. The histological distribution was low grade (1 and 2) in 83 cases (78.3%), and high grade (3) in 23 (21.7%) cases. The architectural pattern was follicular (i.e. nodular, follicular area>75%) in 99 (93.4%) and predominantly diffuse (follicular area<25%) in seven cases (6.6%). Clinical variables that were associated with unfavorable OS were age (>60 years), a high-grade, the presence of B-symptoms, ECOG≥2, high LDH, high B2M and high-risk FLIPI (P<0.05). Variables that were associated with unfavorable PFS were B-symptoms, ECOG≥2, high LDH, high B2M and high-risk FLIPI (P<0.05). Overall, our patient population was reflective of a commonly observed FL population.
Histopathological features of BTLA-positive cells in FL
BTLA-positive-cells were observed either in the germinal centers of follicular areas and in the interfollicular compartment following a T-cell pattern distribution. In reactive tonsils, triple immunofluorescence confirmed the colocalization of PD-1 and BTLA in the FTH cells located in the germinal centers, while FOXP3 was a specific marker for Tregs ( Figure 1G ). In addition, BTLA was positive in the mantle and marginal zone area in 36 (35.6%) of the cases following a pattern of the B-cell staining. The mantle zone was also IgD-positive ( Figure 1) .
The relationship between the percentage of BTLA positive cells with a T-cell distribution in samples at diagnosis and the pathological characteristics of the patients is shown in 
Histopathological features of TNFSF14-positive cells in FL
In reactive tonsil the TNFSF14-positive cells showed a characteristic Golgi staining pattern in the cytoplasm. In the follicular area of reactive tonsil PAX5+lymphocytes also stained positive for TNFRSF14 and were surrounded by CD21+follicular dendritic cells. Macrophages were also MITF+ (Figure 2A) .
In FL, TNFRSF14-positive cells had a histological morphology of B-cell centroblasts and the other positive cells had a morphology of macrophages, especially at the stage of transformation to DLBCL. (Figure 2B-D) .
The relationship between the number of TNFSF14-positive cells in samples at diagnosis and the pathological characteristics of the patients is shown in Table 3 Of note, the presence of a BTLA+mantle also positively correlated with follicular FOXP3 (P=0.003). Follicular TNFRSF14 did not correlate with follicular PD-1 or follicular FOXP3. Total TNFRSF14 did not correlate with total FOXP3 as well. Total TNFRSF14 and total BTLA didn't correlate either as continuous or as ordinal variable.
In the mice system in peyer's patches, B220+CD11C+cells, present in the mantle/marginal zone also expressed BTLA. Interestingly, by flow cytometry FOXP3+Tregs also could express BTLA and/or HVEM. Of note, one must be cautious when comparing mice and human immune system as results cannot be directly translated. Further analysis will be required in the future.
Relationship between the number of BTLA and TNFSF14-positive cells, clinical features and outcome
The total numbers of BTLA and TNFRSF14-positive cells did not correlate with the outcome when analyzed as a continuous variable, but the cohort was divided in two categorical subsets based on high and low positive numbers (Figures 3-5) . High BTLA expression, either in intrafollicular (≥4.54%) or interfollicular (≥8.05%) areas, and total numbers (≥8.59%), correlated with a favorable OS (Kaplan-Meier, Log Rank P=0.005, P=0.024 and P=0.022, respectively); the Hazard Ratio (HR) was 0.382, 0.478 and 0.479, respectively (Figure 3) . The 5-and 15-year OS are shown in Table 4 .1. The presence of a BTLA-positive mantle zone also correlated with favorable OS (P=0.039 and HR of 0.468). BTLA did not correlate with the PFS. High total BTLA inversely correlated with the presence of B-symptoms and high serum LDH (Table 4. 2) (Figure 3 ). When we analyzed only the cases treated with rituximab (R-CHOP and R-CHOP-like), high total BTLA also associated with a good prognosis of the patients (OS) (Figure 5 ).
High TNFRSF14, either follicular (≥44), interfollicular (≥32) and total (≥34.9), correlated with a poor OS: KaplanMeier, Log Rank P=0.000142, P=0.000019 and P=0.000021, respectively; the HR was 3.393, 3.636 and 3.863, respectively ( Figure 4 ). The 5-and 15-year OS is shown in (Table 4. 3). TNFRSF14 associated to a higher risk of FL transformation to DLBCL: total TNFRSF14 (cut-off at 42.1%), odds-ratio 5.250 (95% C.I. 1.250-22.058), P=0.024. Of note, BTLA expression did not associate to FL transformation. In the ritumixab-treated group, high total TNFRSF14 also associated with a poor OS and PFS ( Figure 5 ).
Both total BTLA and total TNFSF14 expression were included with the FLIPI in a Cox model to identify which one was more important to predict OS. TNFRSF14 and FLIPI retained its prognostic value. When tested for PFS only TNFRSF14 retained prognostic value (Table 5) .
Of note, in this series high total FOXP3 (>5%) correlated with a favorable OS (P=0.040, HR: 0.476, 95%CI 0.231-0.983) as well as high follicular PD-1 (>6%, P=0.001, HR:0.364, 95%CI 0.195-0.677). When total BTLA, total TNFRSF14, total FOXP3 and follicular PD-1 expression as well as FLIPI were included in a Cox model, only TNFRSF14 and FLIPI retained prognostic values.
Gene expression analysis
We used the previously published data of gene expression of FL from the series of Dave (Figure 6 ). The GSEA analysis of the NFkB pathway showed an enrichment on the TNFRSF14 high and dead phenotype (the "high risk" group) ( Figure 6 ). The genes of the core enrichment were CXCL3, CCL20, CXCL2, IL6, CXCL6, TNFAIP2, IRF1, NFKBIA, IL8 and IL1B.
DISCUSSION
In this study, we found that the immune checkpoint genes of BTLA and TNFRSF14 (also known as HVEM) are differentially expressed by cells of the immune microenvironment and by the neoplastic FL B-lymphocytes. We found that the immunohistochemical protein expression correlated with the prognosis of the patients with high BTLA expression being associated with good prognosis and high TNFRSF14 expression with poor outcome, as well as with several clinical variables. In addition, we also found that FL transformation to DLBCL (tTL) was associated with a decrease of BTLA expression but an increase of TNFRSF14.
FL is the second most common subtype of non-Hodgkin lymphoma. It is defined as a lymphoma of follicle center B cells, and virtually always demonstrates a growth pattern that is partially follicular. Germinal centers (GCs) are the site of antibody diversification and affinity maturation and as such are vitally important for humoral immunity. 27 One of the hallmarks of the GC function is the progressive increase of affinity antibodies that is the result of the activation-induced cytidine deaminase (AID)-driven somatic hypermutation (SHM) of the antigen-binding variable regions of immunoglobulin (Ig) genes. 27, 28 SHM generates a panel of mutated B cells that are then selected, based on their affinity, to proliferate and differentiate into antibody-secreting plasma cells (PCs) and memory B cells. 27 A mature GC is divided into two compartments with different functions. The centroblasts in the dark zone proliferate in a meshwork of CXCL12-expressing reticular cells, express CXCR4 and AID, and The prognostic relevance of BTLA and TNFRSF14 was maintained when we re-analyzed only the rituximabtreated patients (RCHOP and RCHOP-like).
Overall Survival
Progression free survival The analysis consisted on binary logistic regression between BTLA Total and the different clinicopathological characteristics. High BTLA Total was defined as a percentage >8.58%, and low as <8.58%. In the logistic regression analysis "low" was considered as the reference.
The analysis consisted on binary logistic regression between TNFRSF14 Total and the different clinicopathological characteristics. High TNFRSF14 Total was defined as a percentage >34.75%, and low as <34.75%. In the logistic regression analysis "low" was considered as the reference.
undergo Ig SHM. 29 In the light zone there is high quantity of naïve B lymphocytes and follicular dendritic cells, there the higher-affinity B cells (centrocytes) are positively selected thanks to the function of the follicular T helper cells (TFH). TFH cells drive the higher-affinity B cells proliferation and differentiation into the plasma cells. 30 TFH cells are characterized by a gene expression signature distinct from that of other T-cell subsets, 31 and they can be identified by an array of markers including CXCR5, CXCL13, PD-1 (PDCD1), ICOS, SAP, CD200, BCL6, IL21 and MAF. 32 BTLA was also identified among the genes specifically expressed in TFH cells. 31 BTLA is a lymphoid receptor that inhibits lymphocyte activation and proliferation on interaction with its ligand, TNFRSF14. 33 BTLA suppresses IL21 production from TFH cells and subsequent humoral immune responses. 34 BTLA is widely express in reactive lymph nodes, except in GC B cells. 33 Among normal B cells, the highest BTLA expression is found in naïve B cells (CD20+, IgD+/CD38-). 33 In our study the expression in reactive tonsils confirmed those finding, BTLA was positive in the GCs with colocalization with PD-1+TFH cells, the B lymphocytes of the mantle zones were also positive and in the interfollicular regions BTLA-positive cells were identified with a pattern similar to PD-1. In FL we found that high BTLA expression in the follicular region was associated with an improved OS. These findings are like those that we had previously reported with PD-1 in FL, focusing on the follicular region. 3 In addition, we found that the presence of a BTLA-positive mantle zone, which also stained with IgD, associated with good prognosis in FL. Interestingly, chronic lymphocytic lymphoma also expresses BTLA 33 and it is derived from CD5+B lymphocytes (B1 cells). We found that BTLA expression in T-cells correlated with PD-1 and FOXP3, two markers associated with good prognosis in FL. 1, 3 Functional studies have confirmed the enrichment of TFH cells in the FL microenvironment, which display a specific activation profile characterized by the expression of IL-4 that could sustain FL pathogenesis. 35 Therefore, TFH cells seem to be necessary for the pathogenesis of FL and associates with good clinical evolution. Importantly, as also seen with the PD-1 marker, 3 transformation to DLBCL is associated with a marked reduction of BTLA expression.
TNFRSF14 is the nexus in several signaling pathways and it plays important roles in the immune system, such as T-cell costimulation, regulation of dendritic cell (DC) homeostasis, autoimmune-mediated inflammatory responses, as well as host defense against pathogens.
36
TNFSF14 serves as a bimolecular switch to regulate the host immune response depending on which ligand it engages because TNFRSF14 functions as both a receptor with signal-transducing functions and as a ligand eliciting signaling. As a receptor, TNFRSF14 leads to the activation of NFkB, RELA, AP-1 and AKT pathways that enhances cell proliferation, cytokine production and survival of TNFRSF14-expressing cells. 36, 37 Antigen presenting cells (APCs, i.e. dendritic cells, macrophages and B cells) can express TNFRSF14. As a ligand of BTLA on T cells will induce ITIM phosphorylation, recruitment of SHP-1 and SHP-2 that will downregulate the TCR signaling pathway resulting in reduced cellular activation, proliferation, and cytokine production. 36 Therefore, can inhibit the function of CD8+cytotoxic T cells and CD4+T helper cells, including TFH cells. 34, 38 In our study the expression of TNFRSF14 had a pattern of APCs including dendritic cells-macrophages and B-cells (centroblasts). We found that a high expression correlated with poor prognosis in FL and with transformation to DLBCL. In addition, GSEA analysis found an enrichment towards the "dead and high TNFRSF14 phenotype" of the NF-kB pathway. Of note, the NF-kB pathway is related to the pathobiology and chemoresistance in FL and tFL. 39 It has been reported that deletions of 1p36 and TNFRSF14 mutations are associated with worse prognosis of FL, but in that publication the authors did not analyze the protein expression of TNFRSF14 40 and, unfortunately, in our study we have not analyzed the mutational status. TNFRSF14 receptor gene is among the most frequently mutated genes in germinal center lymphomas and loss of TNFRSF14 leads to cell autonomous activation of B cell proliferation and drives the development of GC lymphomas in vivo. 41 TNFRSF14 deficient lymphoma B cells also induce a tumor supportive microenvironment Table 5 . Multivariate analysis between BTLA Total, TNFRSF14 Total and FLIPI.
Fig 6.
Gene expression analysis of TNFRSF14 in FL. At RNA level, high TNFRSF14 associated with worse OS using the LLMPP FL GSE16131 series. The GSEA plot showed an enrichment of the NFkB pathway towards the FL "dead -high TNFRSF14 phenotype". Protein-protein interaction analysis of the TNFRSF14-NFkB pathway with molecular actions were as follows: green (activation), red (inhibition), blue (binding), pink (posttranslational modification).
marked by exacerbated lymphoid stroma activation and increased recruitment of T follicular helper (TFH) cells in a FL mice model. 41 These changes result from the disruption of inhibitory cell-cell interactions between the TNFRSF14 and BTLA receptors. 41 In our project the expression of TNFRSF14 was independent of the other components of the microenvironment that we had analyzed: follicular TNFRSF14 did not correlate with follicular PD-1 or follicular FOXP3. Total TNFRSF14 did not correlate with total FOXP3 as well. Total TNFRSF14 and total BTLA didn't correlate either as continuous or as ordinal variable. In a similar way, a mutual exclusive pattern of TNFRSF14 and BTLA expression in human FL samples was also described by Michael Boice et al. 41 TNFRSF14 is considered as a tumor suppressor gene but this is when we focus on the effect on BTLA receptor that delivers inhibitory signals. On the other hand, TNFRSF14, which is bidirectional, can also deliver stimulatory signals and therefore could be considered as having a tumor promoting function (Figure 7) . 38, [42] [43] [44] The relationship with deletion, mutation and protein expression remains to be solved in future.
In summary, we found that high BTLA expression is associated with good prognosis, high TNFRSF14 expression with a bad prognosis in FL including a higher risk of transformation, and that tFL expresses low BTLA but high TNFRSF14. These observations suggest that the co-stimulatory and co-inhibitory BTLA-TNFRSF14 pathway plays a relevant role in the pathogenesis of FL. 
